Ambrilia: Data shows high genetic barrier to HIV inhibitor PPl-100

By Elaine Rigoli

Tampa, Fla., June 14 - Ambrilia Biopharma, Inc. presented a scientific poster reporting on the high genetic barrier and favorable cross-resistance profile of its lead HIV protease inhibitor (PI) PPL-100 at the 15th International HIV Drug Resistance Workshop, in Sitges, Spain.

The company said the last decade has marked a major improvement in the treatment of HIV positive patients thanks to the highly active antiretroviral treatment consisting of a cocktail of reverse transcriptase inhibitors and PIs.

Nevertheless, the emergence of multi-resistant viruses continues to challenge the clinical community.

The resistance to PIs is mainly due to the appearance of mutations in the virus, particularly in the protease gene.

For this reason, new antiviral drugs with a high genetic barrier, which makes it more difficult for the virus to develop resistance, need to be developed to fight the emergence of resistant HIV viruses.

"We are very pleased to have been invited to present PPL-100's resistance study results since this event is the premier meeting in HIV drug resistance and innovative approaches to antiretroviral therapy," president and chief executive officer Hans J. Mader said in a news release.

"With no cross-resistance to other PIs amprenavir, lopinavir, atazanavir, saquinavir, indinavir and nelfinavir, and its high genetic barrier, we believe PPL-100 is a very promising first-line treatment for HIV/AIDS and we really look forward to announcing the phase 1a results shortly," he added.

Ambrilia is a biopharmaceutical company located in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.